Lately, there’s been an exciting wave of news about HHT therapies. Several clinical trials are now underway, biotech companies are investing heavily in HHT research, and new treatments are closer than ever to becoming reality.

We’re entering this new “therapeutics era” for HHT, and Dr. Hanny Al-Samkari, Director of the Massachusetts General Hospital HHT CoE, will outline what this transformation means for patients and families. This discussion will include groundbreaking advancements like pomalidomide, pazopanib, Diagonal’s Agonist Antibody, and Vaderis’ VAD044. These treatments represent new hope for managing and treating HHT symptoms more effectively.

Join this free discussion to learn about the science behind these innovations, the progress in clinical trials, and how these breakthroughs could improve the lives of HHT patients. Don’t miss this opportunity to hear directly from an expert about the promising future of HHT care!